Subsequent Events	85 Months Ended
Sep. 30, 2010
Subsequent Events	4. Subsequent Events The Company evaluated all events or transactions that occurred after the balance sheet date through the date these financial statements were available to be issued. During this period the Company did not have any material recognizable subsequent events and one disclosable event. On October 5, 2010, a milestone was reached under the Company’s license agreement with DEKK-Tec, Inc. requiring a $300 thousand payment and vesting of options to purchase 6,904 shares of the Company’s common stock that are exercisable at $0.02 per share. On November 1, 2010, the Company was notified that it was awarded cash grants totaling approximately $733 thousand under the U.S. Government’s Qualifying Therapeutic Discovery Project (“QTDP”) program.

Subsequent Events

85 Months Ended

Sep. 30, 2010

4. Subsequent Events

The Company evaluated all events or transactions that occurred after the balance sheet date through the date these financial statements were available to be issued. During this period the Company did not have any material recognizable subsequent events and one disclosable event.

On October 5, 2010, a milestone was reached under the Company’s license agreement with DEKK-Tec, Inc. requiring a $300 thousand payment and vesting of options to purchase 6,904 shares of the Company’s common stock that are exercisable at $0.02 per share.

On November 1, 2010, the Company was notified that it was awarded cash grants totaling approximately $733 thousand under the U.S. Government’s Qualifying Therapeutic Discovery Project (“QTDP”) program.